Nilotinib Zentiva (Nilotinib)

Nilotinib selectively binds to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, locking the enzyme in an inactive state. This blocks downstream signaling that promotes uncontrolled cell growth. In addition, the drug inhibits KIT and PDGFR kinases, which contributes to its broader antineoplastic activity.

The dosage of Nilotinib Zentiva is individualized by the prescribing physician based on the patient’s disease status, prior therapy, and tolerability. The prescriber determines the exact strength, frequency, and any required dose adjustments, so patients should follow the specific instructions provided by their healthcare professional.

The safety of Nilotinib in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug may pose risks to the fetus or infant. Women of childbearing potential should use effective contraception, and breastfeeding is generally not recommended while receiving Nilotinib.

To request Nilotinib Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor that offers higher potency and selectivity compared with first‑generation agents such as imatinib. Clinical studies have shown faster and deeper molecular responses in many patients, though the safety profile differs, with a higher incidence of cardiovascular and metabolic effects that require monitoring.

Store Nilotinib Zentiva at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original blister pack, protect them from moisture and direct light, and avoid storing in humid or excessively hot environments to maintain product stability.

Nilotinib Zentiva is taken orally, usually as whole tablets with a moderate‑fat meal to improve absorption. Patients should swallow the tablets whole with water and follow the timing and dietary instructions provided by their prescriber to ensure consistent drug exposure.

Serious risks associated with Nilotinib include cardiovascular events such as myocardial infarction or stroke, hepatotoxicity with marked liver enzyme elevations, and pancreatitis. Patients should be monitored regularly for heart symptoms, liver function abnormalities, and signs of pancreatic inflammation, and any concerning findings should prompt immediate medical evaluation.

Nilotinib Zentiva should be avoided in patients with known hypersensitivity to nilotinib or any of its excipients. It is also contraindicated in individuals with uncontrolled cardiovascular disease, active pancreatitis, or severe hepatic impairment. Physicians must assess each patient’s medical history before initiating therapy.